Global biopharmaceutical services provider Allucent announced today that it has partnered with THREAD, an innovative DCT and eCOA technology provider, to launch Allucent Patient Direct Trials.
| Biopharmaceutical Services Provider Allucent Partners with THREAD to Address Modern Clinical Trial Needs of Small and Emerging Biotech Companies News Summary
CARY, N.C., May 23, 2023 /PRNewswire/ -- Global biopharmaceutical services provider Allucent announced today that it has partnered with THREAD, an innovative DCT and eCOA technology provider, to launch Allucent Patient Direct Trials. The new offering brings advanced technologies and development and regulatory expertise to small and emerging biotechnology companies to support them in designing and overseeing customized decentralized clinical trial approaches that address their needs.
Post-COVID-19, Allucent embraced new digital technologies and enhanced its patient-centric approaches and guidance for optimizing clinical protocols. Allucent Patient Direct Trials leverages this experience to address the needs of many small and emerging biotech companies that may not have the in-house resources required to design and oversee DCTs. Working with THREAD, Allucent’s team of regulatory and product development consultants can guide sponsors in determining the most effective and efficient digital strategies for remote engagement and data collection for their studies. Mark A. Goldberg, MD, chairman and chief executive officer of Allucent, stated, “Allucent Patient Direct Trials enables a highly customized, decentralized clinical trial offering that’s laser-focused on meeting the current needs of small and emerging biotech companies. With this launch, we’re helping our clients harness new insights and technologies to be more patient-centric and realize the potential and efficiencies of decentralized approaches to clinical research.” Global pharmaceutical and research organizations have increasingly adopted DCTs to make patient participation more accessible and manageable. Leveraging technology, DCTs can expedite recruiting, help retain participants, and increase the diversity of the overall participant pool so trial results are more representative of real-world effectiveness. The announcement coincides with the 2023 World Orphan Drug Congress, where Allucent will lead a panel session on the value of decentralized study designs and protocol optimization, especially for rare disease therapeutic development. About Allucent
SOURCE Allucent |
View original content to download multimedia:
